Here, in the perspective to identify novel bioactive compounds prospectively usable as novel anti-BC drugs, we challenged the platform with a library of 1018 FDA-approved drugs (i.e., a drug-repurposing approach) seeking compounds directly binding to ERα and inhibiting ERα signaling to cell proliferation in cell lines modeling primary and MBC cells. The gene discussed is ESR1; the disease is breast cancer.